AccScience Publishing / ARNM / Online First / DOI: 10.36922/ARNM025220024
CASE REPORT

A case report of sarcomatoid hepatocellular carcinoma treated multimodality

Cam Phuong Pham1,2,3 Quang Hien Le1,3* Binh Duong Nguyen3 Trong Khoa Mai1,2 Van Thai Pham1,3 Thi Hong Lieu Nguyen4
Show Less
1 The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam
2 Department of Oncology and Nuclear Medicine, University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
3 Department of Nuclear Medicine, Hanoi Medical University, Hanoi, Vietnam
4 Pathology and Cytology Center, Bach Mai Hospital, Hanoi, Vietnam
Received: 31 May 2025 | Revised: 20 June 2025 | Accepted: 21 July 2025 | Published online: 7 August 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Sarcomatoid hepatocellular carcinoma (SHC) is a rare and highly aggressive variant of hepatocellular carcinoma (HCC), characterized by high malignancy, frequent recurrence, and poor prognosis. Definitive diagnosis is based on histopathological criteria to differentiate it from HCC and other malignant tumors in the liver. At present, there is no standardized treatment; surgery remains the primary therapeutic option, while other treatments show only modest effectiveness. We herein present a clinical case of a male patient diagnosed with SHC who experienced multiple recurrences and underwent multimodal treatment, including transarterial chemoembolization, surgery, and systemic chemotherapy.

Keywords
Sarcomatoid hepatocellular carcinoma
Recurrence
Multimodality treatment
Funding
None.
Conflict of interest
Pham Cam Phuong is an Editorial Board Member of this journal but was not involved in any aspect of the editorial or peer-review process of this paper, directly or indirectly. The remaining authors declare no known competing financial interests or personal relationships that could have influenced the work presented in this paper.
References
  1. Yu Y, Zhong Y, Wang J, Wu D. Sarcomatoid hepatocellular carcinoma (SHC): A case report. World J Surg Oncol. 2017;15(1):219. doi: 10.1186/s12957-017-1286-1

 

  1. Zhang C, Feng S, Tu Z, et al. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. Cancer Med. 2021;10(18):6227-6238. doi: 10.1002/cam4.4162

 

  1. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: A special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989;23(S1): S4-S8. doi: 10.1007/BF00647229

 

  1. Marijon H, Dokmak S, Paradis V, et al. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol. 2011;54(5):1073-1078. doi: 10.1016/j.jhep.2010.11.011

 

  1. Obara K, Matsumoto N, Okamoto M, et al. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2(1):116-123. doi: 10.1007/s12072-007-9040-3

 

  1. Lee KB. Sarcomatoid hepatocellular carcinoma with mixed osteoclast-like giant cells and chondroid differentiation. Clin Mol Hepatol. 2014;20(3):313-316. doi: 10.3350/cmh.2014.20.3.313

 

  1. Li J, Gao X, Zhao K, Meng X, Liu S, Zhang J. Hepatocellular carcinoma combined with sarcomatoid hepatocellular carcinoma: A case report. Medicine (Baltimore). 2024;103(4):e37013. doi: 10.1097/MD.0000000000037013
Share
Back to top
Advances in Radiotherapy & Nuclear Medicine, Electronic ISSN: 2972-4392 Print ISSN: 3060-8554, Published by AccScience Publishing